Skip to main content
Addgene

pLXSN-Axl DN
(Plasmid #65223)

Print

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 65223 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pLXSN
  • Backbone manufacturer
    Clontech
  • Backbone size w/o insert (bp) 5900
  • Total vector size (bp) 7400
  • Vector type
    Mammalian Expression, Retroviral
  • Selectable markers
    Neomycin (select with G418)

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    Low Copy

Gene/Insert

  • Gene/Insert name
    AXL DN
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1500
  • Mutation
    deleted cytoplasmic domain
  • GenBank ID
    NM_021913
  • Entrez Gene
    AXL (a.k.a. ARK, AXL3, JTK11, Tyro7, UFO)
  • Promoter LTR

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site EcoRI (not destroyed)
  • 3′ cloning site FspI (destroyed during cloning)
  • 5′ sequencing primer CTCTCCCCCTTGAACCTC
  • 3′ sequencing primer GACTTTCCACACCCTAACTG
    • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Insert contains extracellular and transmembrane domains of AXL.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLXSN-Axl DN was a gift from Axel Ullrich (Addgene plasmid # 65223 ; http://n2t.net/addgene:65223 ; RRID:Addgene_65223)

  • For your References section:

    AXL is a potential target for therapeutic intervention in breast cancer progression. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Keri G, Ullrich A. Cancer Res. 2008 Mar 15;68(6):1905-15. doi: 10.1158/0008-5472.CAN-07-2661. 10.1158/0008-5472.CAN-07-2661 PubMed 18339872
Related items:
Commonly requested with: